Codiak Biosciences Stock
Biotechnology
About Codiak Biosciences Stock
Codiak Biosciences is developing exosomes, natural vesicles that mediate inter-cellular communication, as both a powerful therapeutic modality and an advanced diagnostic system. Codiak is building a world-class team and has generated and acquired foundational intellectual property that will allow it to capitalize on the unique potential of exosome biology.
Investors
Alaska Permanent Fund
Alexandria Venture Investments
ARCH Venture Partners
Codiak Biosciences, Metacrine, Beam Therapeutics, Mindstrong Health
Boxer Capital
Casdin Capital
EcoR1 Capital
Flagship Pioneering
Qatar Investment Authority
Sirona Capital
Yukon Partners
Funding History
| November 2015 | $33.2M |
|---|---|
| November 2015 | $64.2M |
| November 2017 | $76.5M |
Management
Chief Executive Officer
Doug Williams
Chief Business Officer
Richard Brudnick
Chief Financial Officer
Linda C. Bain
Scientific Co-Founder
Raghu Kalluri
Scientific Co-Founder
Eric Lander
Chief Scientist
Jan Lötvall
Press
BusinessWire - Nov, 8 2019
BioSpace - May, 1 2019
exomes - Apr, 30 2019
PR Newswire (press release) - Jun, 4 2018
Business Wire (press release) - Dec, 21 2017
PR Newswire (press release) - Nov, 29 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Codiak Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
